The USFDA recently approved an adjuvanted respiratory syncytial virus (RSV) vaccine for older adults (≥ 60 years) to prevent lower respiratory tract diseases. This approval was based on the findings of the phase III clinical trial that helped establish the efficacy of this vaccine. Overall efficacy – 82.6% (96.95% CI, 57.9-94.1) Efficacy in older adults with at least one co-morbidity, including endocrine-metabolic or cardiorespiratory conditions – 94.6% (95% CI, 65.9-99.9) Efficacy against severe RSV – 94% (95% CI, 62.4-99.9) Vaccine Details Do you think the RSV vaccine will be useful in preventing lower respiratory tract diseases in the elderly population?
Source: USFDA Suggested Reading Respiratory Syncytial Virus: A New Challenge ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no warranties,…
